$VERU

Veru Inc

  • NASDAQ
  • Consumer Non-Durables
  • Household/Personal Care
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$8.39 ▲3.708%

Extented Hours

VOLUME

341,024

DAY RANGE

8.09 - 8.3

52 WEEK

2.3 - 24.57

Join Discuss about VERU with like-minded investors

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Thursday, August 12, 2021 Futures Up/Down % Last Dow 40.00 0.12% 35,413 S&P 500 2.25 0.05% 4,442 Nasdaq 5.50 0.04% 15,025 Another day, another record high for the Dow and S&P 500 as futures are pointing to a slightly higher open, building on the ongoing upside momentum that pushed the S&P 500 to its 45th all-time high Wednesday. Both the Dow Jones Industrial Average and S&P 500 are coming off all-time bests as consumer prices (CPI) data indicated U.S. inflation was in-line with estimates, raising hopes that growth may have peaked, while sectors tied to economic growth such as industrials, materials and metals advanced a second day on the heels of the passage of a large infrastructure bill. The July consumer price index increased 0.5% last month after climbing 0.9% in June, though on a YoY basis was above 5% again (ahead of today’s PPI data at 8:30 AM ET). Meanwhile, two Fed members (George and Kaplan) each said the central bank should announce its timeline to reduce its massive bondholding, with Kaplan calling for it to begin next month, with tapering to begin in October. Healthcare was also a drag on markets as S&P components MRNA and PFE fell after the drug regulator of the European Union said it was looking into new possible side-effects of mRNA COVID-19 shots. Asian shares dropped for the first time this week as China stepped up scrutiny of its insurance technology platforms while European stocks drift on mixed earnings results. The Nikkei Index slipped -55 points to 28,015, the Shanghai Index slid -7 points to 3,524, and the Hang Seng Index dropped -142 points (0.535) to settle at 26,517. In Europe, the German DAX is up over 60 points to 15,888, while the FTSE 100 is down a few points at 7,210. Events Calendar for Today 8:30 AM ET Weekly Jobless Claims…est. 375K 8:30 AM EST Continuing Claims…est. 2.88M 8:30 AM ET Producer Price Index (PPI) MoM for July…est. 0.6% 8:30 AM ET PPI Ex: Food & Energy (core) MoM for July…est. 0.5% 8:30 AM ET Producer Price Index (PPI) YoY for July…est. 7.3% 8:30 AM ET PPI Ex: Food & Energy (core) YoY for July…est. 5.6% 10:30 AM ET Weekly EIA Natural Gas Inventory Data 1:00 PM ET U.S. to sell $27 bln in 30-year bonds Earnings Calendar: Earnings Before the Open: AVXL, AZEK, BDR, BODY, BR, BTTR, CELH, EFOI, EMAN, EYE, FSTX, GRWG, HOOK, KELYA, MDP, MIDD, MKTW, NYC, PGTI, SOHO, TAST, UP, UTZ, VERU Earnings After the Close: ABNB, ACHV, AFIB, APDN, ASTR, AWH, BBI, BIOL, BLBD, BOXL, BW, CAPR, CODX, CRMD, DASH, DCO, DIS, EAR, FIGS, FLO, FRGI, HOFV, ICCC, INTZ, IPWR, KINS, LAZR, LIVX, LMB, LVOX, LZ, MOTS, OPGN, PHUN, PTE, SFE, SGHT, SOFI, TLMD, TPCS, VIVE, WISH, XL Other Key Events: BTIG HIMSS Digital Health Booth Tour (virtual), 8/11-8/12 Canaccord Genuity 41st Annual Growth Conference (virtual), 8/10-8/12 Cowen Annual Communications Infrastructure Hybrid Summit, 8/9-8/12 Cowen 9th Annual Internet & Media Bus Tour (virtual), 8/9-8/13 Credit Suisse 4th Annual FinTech Conference (virtual), 8/11-8/13 JPMorgan Auto Conference (virtual), 8/11-8/12 KeyBanc Capital Markets Technology Leadership Virtual Forum, 8/9-8/12 Oppenheimer 24th Annual Technology, Internet & Comm Conference (virtual), 8/10-8/12 Piper Biotech Virtual Tour, 8/10-8/12 UBS Financial Services Conference (virtual), 8/10-8/12 Market Closing Prices Yesterday The S&P 500 Index gained 10.95 points, or 0.25%, to 4,447.70 The Dow Jones Industrial Average rose 220.30 points, or 0.62%, to 35,484.97 The Nasdaq Composite slipped -22.95 points, or 0.16%, to 14,765.14 The Russell 2000 Index advanced 10.98 points, or 0.49% to 2,250.34 Macro Up/Down Last Nymex -0.08 69.17 Brent -0.04 71.40 Gold 1.10 1,752.80 EUR/USD -0.0002 1.1737 JPY/USD -0.02 110.41 10-Year Note -0.008 1.351% World News The International Energy Agency (IEA) cut its outlook for global oil demand “sharply” for the rest of 2021 as the resurgence of coronavirus rocks major consumers and predicted a new surplus in 2022. The IEA cut its 2021 global oil demand growth forecast by 100,000 barrels a day, while upgrading its 2022 forecast by 200,000 barrels a day Eurozone Jun Industrial Production: m/m -0.3% vs -0.2% consensus; y/y 9.7% vs 10.4% consensus UK Q2 GDP: q/q 4.8% in-line; y/y 22.2% vs 22.1% consensus; UK Jun GDP: 1.0% vs 0.8% consensus; UK June Trade Balance: -£11.99b vs -£9.1b consensus; K June Ind Production m/m 0.7% vs 0.3% consensus, y/y 8.3% vs 9.4% consensus Sector News Breakdown Consumer DoorDash ($DASH) is said to have held talks to purchase Instacart over the past two months that may have valued the grocery delivery company at $40B to $50B. The talks felt apart in recent weeks at least partly over regulatory concerns, according to a report in The Information https://bit.ly/2VKi4F5 Core-Mark Holding ($CORE) said the waiting period under the HSR act for Performance Food Group’s (PFGC) planned purchased expired on Aug. 9 and the closing conditions for the deal have been satisfied Fisker Inc ($FSR) announces private offering of $600 mln 5-yr convertible notes Nio ($NIO) Q2 non-GAAP EPS loss (-$0.03) vs. est. loss (-$0.11); Revenue of $1.31B (+127% Y/Y) beats by $20M; said achieved a record-high quarterly delivery of 21,896 vehicles in Q2, followed by 7,931 vehicles in July, bringing the cumulative deliveries of NIO vehicles to 125,528 as of July 31, 2021 Blink Charging ($BLNK) 2Q EPS ($0.32) vs est. ($0.16) on revs $4.4Mm vs est. $2.6Mm eBay Inc. ($EBAY) Q2 adj EPS $0.99 vs. est. $0.95; Q2 revs $2.7B vs. est. $3.00B; expands share repurchase authorization by an additional $3B; entered agreement to sell about 135M shares of eBay’s Adevinta stock to Permira for over $2.4B, reducing ownership to 33%; announced an agreement to sell 80.01% of eBay Korea business to eMart for about $3B; guides Q3 revs $2.42B-$2.47B vs. est. $2.92B; annual active sellers grew by 5%, for total of 19M global active sellers Fossil Group ($FOSL) 2Q EPS ($0.02) on sales $411Mm; sees 3Q net sales +5-10%; guides FY net sales growth to approx +14-17%; Lordstown Motors ($RIDE) 2Q EPS ($0.61) vs est. ($0.49); pursuing external capital sources including debt and equity-linked securities; sees FY op exp $95-105Mm, expects to end 3Q with liquidity between 225-275Mm cash and equivalents without any funds from a capital raise Utz Brands ($UTZ) Q2 adj EPS 13c vs. est. 15c; Q2 revs $299.2M vs. est. $290.29M; sees FY 2021 adjusted shr $0.55 to $0.60; believes that consumer demand for its products will remain strong in second half of fiscal 2021; says continue to expect fiscal 2021 net sales consistent with fiscal 2020 pro forma net sales Vroom ($VRM) Q2 adj EPS loss (-$0.48), in-line with consensus; Q2 revs $761.89M vs. est. $637.99M; for Q2, had18,268 ecommerce units sold, up 172% YoY; Ecommerce revenue of $579.7 million, up 230% YoY; Ecommerce gross profit of $49.6 million, up 588% YoY Energy Array Technologies ($ARRY) 2Q EPS $0.00 vs est. $0.01 on revs $202.8Mm vs est. $231Mm; guides FY revs $850-940Mm vs est. $1B, sees FY adj EPS $0.15-0.25 vs est. $0.37 EnerSys ($ENS) Q adj EPS $1.25 vs est. $1.20 on revs $814.9Mm vs est. $810.5Mm, backlog grew $157Mm; guides 2Q adj EPS $1.03-1.13 vs est. $1.28 Canadian Solar ($CSIQ) Q2 EPS $0.18 vs. est. loss (-$0.30); Q2 revs $1.43B vs. est. $1.43B; Q2 solar module shipments of 3.7 GW, top end of 3.5 GW to 3.7 GW guidance; sees Q3 revs $1.2B-$1.4B vs. est. $1.62B; reducing its full year 2021 total module shipment guidance to 16 GW to 17 GW; reiterates its project sales guidance and total battery storage shipment guidance for FY 2021; carve-out IPO of CSI solar subsidiary remains on track Financials AllianceBernstein L.P. ($AB) preliminary assets under management increased to $748 billion during July 2021 from $738 billion at the end of June. Market appreciation and modest firmwide net inflows drove the 1% increase. Manning & Napier, Inc. ($MN) reported preliminary assets under management (“AUM”) as of July 31, 2021 of $22.5 billion, compared with $22.3 billion at June 30, 2021 Victory Capital Holdings, Inc. ($VCTR) reported assets under management (AUM) of $162.9 billion as of July 31, 2021. Opendoor Technologies (OPEN) Q2 EPS loss (-$0.24) vs. est. loss (-$0.34); Q2 revs $1.2B vs. est. $1.09B; Gross profit of $159 million, up 64% versus 1Q21; gross margin of 13.4%, up 40 basis points versus 1Q21; Adjusted EBITDA of $26 million versus ($2) million in 1Q21; adjusted EBITDA margin of 2.2% versus (0.3%) in 1Q21; sees Q3 revenue $1.8B-$1.9B vs. est. $1.52B Healthcare In vaccine news, NBC reports that the FDA would authorize a third shot of coronavirus vaccine as soon as Thursday for certain people with weakened immune systems. The decision to expand the emergency use of the vaccines from Moderna ($MRNA) and the Pfizer ($PFE)/BioNTech ($BNTX) shots Amwell ($AMWL) Q2 EPS loss (-$0.15) vs. est. loss (-$0.19); Q2 revs $60.2M vs. est. $61.7M; Q2 gross margins increased 600 bps to 44% of revenue versus 38% last quarter; said total visits of 1.3 million versus 1.6 million last quarter; lowers year revs to $252M-$262M from $260M-$270M and narrows year adj Ebitda loss view Fulcrum Therapeutics ($FULC)6M share secondary priced at $19.00 GoHealth ($GOCO) 2Q EPS ($0.12) vs est. ($0.04) on revs $196.9Mm vs est. $175.1Mm; guides FY revs $1.2-1.3B vs est. $1.24B, sees FY adj EBITDA $300-330Mm Hims & Hers ($HIMS) Q2 EPS loss (-$0.05) vs. est. loss (-$0.10); Q2 revs $60.7M vs. est. $56.49M; sees Q3 revs $69M-$71M vs. est. $58.31M and sees year revs $251M-$255M vs. est. $226.3M Xeris Pharmaceuticals ($XERS) announced it has received U.S. FDA clearance for phase 1 clinical trials for its hypothyroidism treatment Industrials & Materials Apogee Enterprises ($APOG) announced plans to realign and simplify its business structure to “bring a stronger focus to serving customers, enable a more competitive cost model, and better position the company for future growth and improved profitability; now expects to achieve $20M-$30M of annualized savings by the end of fiscal 2023 Royal Gold ($RGLD) 4Q EPS $1.25 vs est. $0.92 on revs $168Mm vs est. $165Mm; guides 1Q stream segment sales 62,000-67,000 GEOs with qtr-end inventory 22,000-27,000 GEOs Gates Industrial ($GTES) 25M share Secondary priced at $16.00

59 Replies 11 👍 11 🔥

profile
@thegiz18 #ivtrades
recently

Good morning, nice earnings bounce on $SONO, $CLOV, $VERU

113 Replies 8 👍 13 🔥

profile
@Navneet #droscrew
recently

waiting for phase 3 results for $veru

74 Replies 6 👍 13 🔥

profile
@Navneet #droscrew
recently

he is betting on $veru now

58 Replies 7 👍 14 🔥

profile
@CarlosH #ivtrades
recently

On watch $VERU

62 Replies 10 👍 12 🔥

profile
@viking #StockTraders.NET
recently

Upside: -RMED +45% (momentum) -LMNL +44% (momentum following FDA approval for its Biologics License Application for Ryplazim) -USCR +28% (to be acquired by Vulcan Materials for $74.00/shr in cash valued at $1.29B) -QTS +21% (to be acquired by Blackstone at $78.00/shr for a total transaction value of $10B) -BNGO +14% (names Jason Priar as its Chief Commercial Officer) -EVFM +14% (momentum) -MIC +12% (confirms to sell Atlantic Aviation unit for $4.48B in cash and assumed debt and reorganization obligations) -CDXC +11% (ChromaDex and Walmart launch Tru Niagen in 3,800 (from 3K prior) Walmart Stores Across the United States) -GIII +8.1% (earnings, guidance) -BLUE +7.4% (announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and ß-Thalassemia Studies) -VERU +5.0% (announces positive data at ASCO) -BIIB +4.7% (Biogen and Bio-Thera announce positive results from Phase 3 study of BAT1806) -NOVN +2.3% (results from Novan’s Exploratory Studies further demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health) -KKR +1.1% (MIC confirms to sell Atlantic Aviation unit for $4.48B in cash and assumed debt and reorganization obligations) Downside: -MOSY -12% (files to sell 1.8M shares at $7.15/shr for a total value of $13M) -PIXY -7.3% (files to sell up to 10.1M shares for holders) -WERN -2.0% (hearing cut at Goldman Sachs to Sell from Neutral) -MSTR -1.2% (to incur $284.5M impairment loss in Q2 due to fluctuations in Bitcoin; files to sell $400M of Senior secured 2028 notes)

65 Replies 6 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

all covered $VERU

84 Replies 6 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

had a $10.6 avg on $VERu wish I held some size

46 Replies 9 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

yikes $VERU

125 Replies 7 👍 11 🔥

PR
@proj8 #StockTraders.NET
recently

short watch $VERU $MVIS $ATNX

136 Replies 8 👍 10 🔥

XX
@xX_Drip_Gawd_Xx #StockTraders.NET
recently

$VERU ANNOUNCES THE PRESENTATION OF POSITIVE PHASE 2 CLINICAL DATA OF ENOBOSARM

105 Replies 11 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$VERU on watch

94 Replies 15 👍 14 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: $OCGN, $DPW, $VERU, $ATNX.....also watching $SKLZ post earnings

44 Replies 9 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

nice $VERU offering

73 Replies 8 👍 12 🔥

BR
@brAli #StockTraders.NET
recently

$veru Hod break

131 Replies 10 👍 7 🔥

profile
@viking #StockTraders.NET
recently

$VERU earnings tomorrow morn guys..fyi

100 Replies 10 👍 8 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

$veru nice into close

125 Replies 14 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

missed the long on $VERU

124 Replies 15 👍 14 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

ss $veru earlier as well

106 Replies 13 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

almost got clipped on $VERU but covered for a gain

89 Replies 15 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

22.50s needs to peak out some on $VERU

52 Replies 7 👍 11 🔥

profile
@Navneet #droscrew
recently

i should have taken few $veru

84 Replies 12 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

woo $VERU what a nice short

114 Replies 9 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$VERU going

148 Replies 6 👍 12 🔥

profile
@Navneet #droscrew
recently

$veru i rolled yesterday

108 Replies 11 👍 10 🔥

IN
@In2Learn #droscrew
recently

$VERU and $AI today damn lost my focus

80 Replies 8 👍 7 🔥

profile
@Navneet #droscrew
recently

$veru 15 calls feb expiry

134 Replies 8 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$VERU going

91 Replies 14 👍 15 🔥

profile
@Navneet #droscrew
recently

$veru $vgac today was amazing

102 Replies 10 👍 9 🔥

profile
@maletone #StockTraders.NET
recently

$veru on watch tomorrow for a short

126 Replies 14 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

earnigns coming up on $VERU

63 Replies 9 👍 7 🔥

profile
@viking #StockTraders.NET
recently

$VERU looking toppy

78 Replies 11 👍 6 🔥

profile
@Navneet #droscrew
recently

$veru popped

82 Replies 12 👍 9 🔥

profile
@viking #StockTraders.NET
recently

these will expire worthless. took hit on this one. still holding the APR 16 5 PUTs though > @rrivy said: long $VERU APR 16 5 PUT

72 Replies 15 👍 11 🔥

profile
@viking #StockTraders.NET
recently

$VERU popping for no apparent reason

64 Replies 9 👍 7 🔥

profile
@Navneet #droscrew
recently

$veru flow ! they have some presentation on jan 11

86 Replies 7 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

$VERU hitting scan

143 Replies 13 👍 8 🔥

profile
@maletone #StockTraders.NET
recently

$VERU covered to early yesterday

149 Replies 14 👍 12 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

care to share with us what youve found on $veru?

106 Replies 15 👍 9 🔥

profile
@viking #StockTraders.NET
recently

did a bit of digging into $VERU. some big red flags.

65 Replies 13 👍 9 🔥

profile
@viking #StockTraders.NET
recently

are you short $VERU?

80 Replies 14 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

nice on $VERU

107 Replies 7 👍 6 🔥

profile
@viking #StockTraders.NET
recently

long $VERU JAN 15 5 PUT

108 Replies 12 👍 9 🔥

profile
@viking #StockTraders.NET
recently

long $VERU APR 16 5 PUT

41 Replies 15 👍 9 🔥

profile
@viking #StockTraders.NET
recently

out $VERU moved position to long puts

140 Replies 15 👍 11 🔥

profile
@viking #StockTraders.NET
recently

going short $VERU now

99 Replies 8 👍 15 🔥

profile
@viking #StockTraders.NET
recently

out $VERU ..didnt get the pop

125 Replies 13 👍 11 🔥

profile
@viking #StockTraders.NET
recently

im gonna go long $VERU here thinking spike into close but very short leash.

146 Replies 8 👍 10 🔥

profile
@viking #StockTraders.NET
recently

$VERU wouldnt be suprised if they pumped it into close then did an offering after the bell

150 Replies 13 👍 6 🔥

profile
@viking #StockTraders.NET
recently

did $VERU do an offering yet?

121 Replies 13 👍 9 🔥

Key Metrics

Market Cap

654.80 M

Beta

1.34

Avg. Volume

488.90 K

Shares Outstanding

79.85 M

Yield

0%

Public Float

0

Next Earnings Date

2021-12-08

Next Dividend Date

Company Information

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.

CEO: Overton Parrish

Website:

HQ: 48 NW 25th St Ste 102 Miami, 33127-4442 Florida

Related News